Jul 26, 2021
By Robert Popovian & Mark Atalla July 16, 2021 Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003. While there has been significant discussion about aducanumab’s...
Jun 28, 2021
by Terry Wilcox & William Smith June 22, 2021 While the last year was very difficult for millions of Americans, it was also a period of rapid innovation as leaders in government and the private sector worked to combat a global pandemic. As a result, about half the...
Jun 11, 2021
In this space, we spend a great deal of time talking about the methods some health economists use to measure health outcomes and the value of new treatments. For example, we’ve gone to some lengths to explain why analyses and valuations based on the quality...
May 14, 2021
In 2018, the UK’s National Institute for Health and Care Excellence (NICE) produced a valuation study that ultimately recommended that researchers replace the EQ-5D-3L quality of life measure with a modified instrument called the EQ-5D-5L. A lengthy debate ensued....
May 3, 2021
On April 16, 2021, the Institute for Clinical and Economic Review (ICER) released its final evidence report on two new treatments for lupus nephritis: Benlysta (manufactured by GlaxoSmithKline) and Lupkynis (Aurinia Pharmaceuticals). In the report, ICER claims to have...
Apr 23, 2021
After years of perpetually rising healthcare costs – not to mention a worldwide pandemic – many elected officials and policymakers – at both the state and federal level – are looking for ways to bring down the cost of public health programs. More and more often, these...
